Physician profile
Michael M Long
NPI 1447224050
$2,656.94
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $621 · 2021: $1,088 · 2022: $42.68 · 2023: $18.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $379.60 | 2019-2021 | |
| Astellas Pharma US INC | $200.44 | 2020-2023 | Xtandi |
| Merck Sharp & Dohme LLC | $138.77 | 2019-2021 | |
| Celgene Corporation | $137.75 | 2019-2021 | |
| Amgen INC. | $132.91 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $128.12 | 2019-2021 | |
| Aurobindo Pharma USA, INC. | $127.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $126.74 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $117.71 | 2019-2021 | |
| Daiichi Sankyo INC. | $112.11 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $101.95 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $97.39 | 2019-2021 | |
| Puma Biotechnology, INC. | $87.16 | 2019-2021 | |
| Clovis Oncology, INC. | $64.85 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $64.24 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $59.24 | 2020-2021 | |
| Pfizer INC. | $45.48 | 2019-2021 | |
| Genentech USA, INC. | $40.05 | 2019-2021 | |
| Abbvie INC. | $38.39 | 2019 | |
| Emd Serono, INC. | $34.98 | 2019-2021 | |
| Glaxosmithkline, LLC. | $33.97 | 2020-2021 | |
| Kite Pharma, INC. | $33.69 | 2020 | |
| Incyte Corporation | $31.90 | 2019-2020 | |
| Array Biopharma INC | $30.61 | 2019-2022 | |
| Eisai INC. | $26.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.06 | 2019 | |
| Seagen INC. | $23.29 | 2020 | |
| Epizyme, INC. | $21.97 | 2020 | |
| Lilly USA, LLC | $20.90 | 2019 | |
| Karyopharm Therapeutics INC. | $19.56 | 2020 | |
| Dova Pharmaceuticals | $19.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.72 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.81 | 2020 | |
| Gilead Sciences, INC. | $16.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.80 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.62 | 2020 | |
| Blueprint Medicines Corporation | $12.55 | 2020 | |
| Csl Behring | $12.49 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.